Clinic
Texas Health Harris Methodist Hospital Hurst-Euless-Bedford
Texas Health Harris Methodist Hospital Hurst-Euless-Bedford was paid $3.57M by Medicaid between Feb 2020 and Dec 2024, across 70 billing codes. Its largest line is 99284, emergency room visit (serious) — 42% of everything it billed.
33Billing provider infoTEXAS HEALTH HARRIS METHODIST HOSPITAL HURST-EULESS-BEDFORD
BEDFORD, TX 76022
BEDFORD, TX 76022
33aNPI1104845015assigned 07/19/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$3.57M
24GClaims85,283
24DCodes billed70
24AFirst – last monthFeb 2020 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#98 of 320
Median peer was paid$205K
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MINCHER, JEFF controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 633 | $34K | |
| 2021 | 19,930 | $757K | |
| 2022 | 30,078 | $1.21M | |
| 2023 | 23,948 | $1.15M | |
| 2024incomplete | 10,694 | $427K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 42% | 8,738 | 8,097 | $1.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 15,308 | 14,625 | $767K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 11% | 2,693 | 2,630 | $392K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.4% | 6,797 | 6,568 | $121K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.2% | 1,042 | 978 | $114K |
| 80053 | Comprehensive metabolic panel | 2.5% | 8,010 | 7,154 | $90K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 1,871 | 1,796 | $90K |
| 87631 | 1.8% | 564 | 548 | $66K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 9,648 | 8,263 | $64K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 2,569 | 2,413 | $61K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 497 | 484 | $44K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.0% | 266 | 246 | $37K |
58 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,680 | $28K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 646 | $27K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 409 | $24K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 365 | $18K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 503 | $18K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 388 | $13K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 258 | $12K |
| 76801 | <1% | 195 | $12K | |
| CP007 | <1% | 223 | $9K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,349 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 407 | $8K |
| 84703 | <1% | 1,381 | $8K | |
| 81001 | <1% | 2,348 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 926 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,027 | $5K |
| 93976 | <1% | 110 | $5K | |
| 84484 | <1% | 1,276 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,093 | $4K |
| 84702 | <1% | 384 | $4K | |
| 83690 | <1% | 1,322 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 676 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 468 | $3K |
| 81025 | <1% | 426 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 98 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 54 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 54 | $1K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 71 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $866.52 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 21 | $865.82 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 207 | $778.44 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,290 | $740.44 |
| 83880 | <1% | 54 | $729.87 | |
| 81003 | <1% | 408 | $645.46 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 56 | $634.06 |
| 83605 | <1% | 181 | $573.99 | |
| 86901 | <1% | 277 | $539.47 | |
| 83735 | <1% | 226 | $509.66 | |
| 87081 | <1% | 64 | $342.89 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 26 | $282.50 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 570 | $275.61 |
| 85610 | <1% | 153 | $258.81 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 319 | $257.17 |
| 94760 | <1% | 48 | $214.02 | |
| 96376 | <1% | 66 | $202.58 | |
| 87040 | <1% | 68 | $202.09 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 88 | $181.83 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15 | $136.26 |
| 86850 | <1% | 14 | $107.32 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 40 | $53.56 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 42 | $43.89 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 40 | $40.51 |
| 85379 | <1% | 15 | $37.31 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 68 | $30.94 |
| 86900 | <1% | 14 | $25.61 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,794 | $23.70 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 17 | $17.40 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 12 | $2.88 |
| A9270 | Non-covered item or service | 0% | 1,937 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMINCHER, JEFF (SENIOR VP REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Texas Health Harris Methodist Hospital Fort Worth | Fort Worth, TX | $13.83M |
| Texas Health Arlington Memorial Hospital | Arlington, TX | $8.23M |
| Texas Health Presbyterian Hospital Dallas | Dallas, TX | $5.33M |
| Texas Health Harris Methodist Hospital Southwest Fort Worth | Fort Worth, TX | $5.20M |
| Texas Health Presbyterian Hospital Kaufman | Kaufman, TX | $4.09M |
| Texas Health Presbyterian Hospital Denton | Denton, TX | $3.84M |
| Texas Health Harris Methodist Hospital Stephenville | Stephenville, TX | $3.69M |
| Texas Health Presbyterian Hospital Plano | Plano, TX | $2.32M |
| Texas Health Harris Methodist Hospital Cleburne | Cleburne, TX | $2.31M |
| Texas Health Harris Methodist Hospital Azle | Azle, TX | $2.14M |
| Texas Health Harris Methodist Hospital Alliance | Fort Worth, TX | $986K |
| Texas Health Presbyterian Hospital Allen | Allen, TX | $965K |
| Texas Health Hospital Frisco | Frisco, TX | $473K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.